Anvisa cancels registration of Duchenne muscular dystrophy therapy Elevidys

Brazil's health regulator, Anvisa, revoked the conditional registration of the gene therapy Elevidys at the request of Roche. The decision follows a failure to meet regulatory data requirements, marking a significant setback for the availability of the treatment in the Brazilian market.